


I hereby certify that this correspondence is being filed via
EFS-Web with the United States Patent and Trademark Office
on April 11, 2007

TOWNSEND and TOWNSEND and CREW LLP

By: 
Anna Kundel

PATENT
Attorney Docket No.: 015280-500100US
Client Ref. No.: E-046-2004/0-PCT-02
Customer No.: 45115

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

PASTAN *et al.*

Application No.: 10/580,635

Filed: Herewith

For: MUTATED ANTI-CD22
ANTIBODIES AND
IMMUNOCONJUGATES

Confirmation No. 4374

Examiner: Not yet assigned

Art Unit: Not yet assigned

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

PRELIMINARY AMENDMENT

Attn: Mr. Shakeel Ahmed
Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) mailed February 14, 2007, Applicants submit herewith the required paper copy and computer readable copy of the Substitute Sequence Listing. Please amend the specification as follows.

Appl. No. 10/580,635
Amdt. dated April 11, 2007
Reply to Notification of Missing Requirements of February 14, 2007

PATENT

Amendments to the Specification begin on page 3 of this paper.

Remarks/Arguments begin on page 14 of this paper.